Fundraising Fox
/Companies
Sign in

Calithera Biosciences

Defunct

South San Francisco, US · Founded 2010 · 25 employees on LinkedIn · 3 known investors

Find your way into Calithera Biosciences

Sign up to see every warm intro you have to Calithera Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Calithera Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.

Biotech

Founders & leadership

Calithera Biosciences was founded in 2010 by Susan M. Molineaux.

SM
Susan M. MolineauxFounder · President and Chief Executive OfficerSusan M. Molineaux co-founded Calithera Biosciences in 2010 and serves as President and CEO. She previously co-founded Proteolix in 2003, where she held senior scientific and leadership roles and led development of the proteasome inhibitor carfilzomib; Proteolix was acquired by Onyx Pharmaceuticals in 2009. Molineaux holds a B.S. in Biology from Smith College, a Ph.D. in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.
WWWilliam Waddill
William WaddillSr. Vice President, Chief Financial Officer2014–2016William Waddill served as Senior Vice President and CFO at Calithera Biosciences, where he oversaw equity financing including an $80 million IPO in 2014. He holds a BS in accounting from the University of Illinois, Chicago, and has spent over 30 years in biotechnology finance following early career roles in commercial banking and public accounting at PwC and Deloitte.

Board

JM
Jean M. GeorgeBoard director
DPDeepa Pakianathan
Deepa PakianathanLead Director and Independent Board Member2010–2023General Partner at Delphi Ventures
RE
Ralph E. ChristoffersenBoard director
JD
Jonathan DrachmanBoard director

Investors · 3

Venture Capital Investment Managementlisted by Venture Capital Investment ManagementSan Francisco

How we know: Venture Capital Investment Management's portfolio page · Not right? Tell us

The Column GroupreportedSan Francisco · $30M

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$16M disclosed across 1 round · 2014

▶$16MraisedJul 2014 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Susan M. MolineauxExecutive Officer, Director
  • Jean M. GeorgeDirector
  • William WaddillExecutive Officer
  • Deepa PakianathanDirector
  • Jonathan DrachmanDirector
  • Ralph E. ChristoffersenDirector
Offering amount
$30M
Amount sold
$16M
First sale
Jul 2014
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Calithera Biosciences do?
Calithera Biosciences was a clinical-stage biopharmaceutical company developing small-molecule oncology drugs targeting tumor metabolism, including the glutaminase inhibitor telaglenastat.
Who founded Calithera Biosciences?
Calithera Biosciences was founded by Susan M. Molineaux in 2010.
Who are Calithera Biosciences's investors?
Calithera Biosciences's investors include Longwood Fund, Venture Capital Investment Management, The Column Group.
How much funding has Calithera Biosciences raised?
Calithera Biosciences has disclosed $16M raised across 1 round.
Where is Calithera Biosciences headquartered?
Calithera Biosciences is headquartered in South San Francisco, US.